Pulmonx Corporation (LUNG) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Pulmonx Corporation (LUNG)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

6.85

-0.20 (-2.84%)

At close: Jan 14, 2025, 3:59 PM

6.84

-0.15%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	5.3
Market Cap	270.49M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.47
PE Ratio (ttm)	-4.66
Forward PE	n/a
Analyst	Buy

Ask	10.87
Volume	226,873
Avg. Volume (20D)	231,109
Open	7.09
Previous Close	7.05
Day's Range	6.80 - 7.27
52-Week Range	5.46 - 14.84
Beta	undefined

About LUNG

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Oct 1, 2020

Employees 279

Stock Exchange NASDAQ

Ticker Symbol LUNG

Website https://pulmonx.com

Analyst Forecast

According to 6 analyst ratings, the average rating for LUNG stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 75.18% from the latest price.

Buy 66.67%

Hold 33.33%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Pulmonx Corporation is scheduled to release its earnings on Feb 19, 2025, during market hours.
Analysts project revenue of $22.29M, reflecting a 15.62% YoY growth and earnings per share of -0.45, making a 25.00% increase YoY.

Why Price Moved

8 months ago · Source

+21.5%

Pulmonx shares are trading higher after the compan... Unlock content with Pro Subscription

8 months ago · Source

+1.45%

Pulmonx shares are trading higher after the company reported better-than-expected Q1 financial results.

News

1 month ago · zacks.com

Does Pulmonx (LUNG) Have the Potential to Rally 117.74% as Wall Street Analysts Expect?

The consensus price target hints at an 117.7% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimat...

1 month ago · businesswire.com

Pulmonx Partners with American Lung Association to Launch New Educational Initiatives for COPD Patients and Providers

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, and the American Lung Association are c...

2 months ago · zacks.com

Wall Street Analysts Predict an 89.61% Upside in Pulmonx (LUNG): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 89.6% in Pulmonx (LUNG). While the effectiveness of this highly sought-after metric is questionable, the positi...

2 months ago · zacks.com

Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates

Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.39 per share a year ago.